-
Ark Biopharmaceutical Enters Into Exclusive License Agreement For Novel ADHD Treatment AZSTARYS® In Greater China, With Affiliate Of Gurnet Point Capital
SHANGHAI, December 28, 2021 -- Shanghai Ark Biopharmaceutical Co., Ltd., an innovative biopharmaceutical company with a depth of expertise in pediatric drug development, today announced that Ark Biopharmaceutical Limited, a wholly-owned subsidiary of ArkBio, entered into an exclusive license agreement with Commave Therapeutics, SA (Commave), an affiliate of Gurnet Point Capital (GPC), a private investment firm focused on the life sciences and medical technology sectors. The license agreement provides for exclusive rights to develop, manufacture, and commercialize the first-in-class once-daily attention deficit hyperactivity disorder (ADHD) treatment AZSTARYS® (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) in Greater China, including mainland China, Hong Kong, Macau, and Taiwan.
TOP